Retatrutide & GLP-1 Peptide Research
An independent reference for retatrutide and the wider incretin literature — GLP-1, GIP and glucagon. Trial evidence, approval-status tracking, COA and HPLC verification methodology, and laboratory calculators. For in-vitro laboratory research use only.
- RET-20-C-2604-001 99.841% Highest published HPLC result · task 150762
- RET-20-V-2604-001 99.741% Full panel · assay, endotoxin, heavy metals, TFA
- RT-40-V-001 99.692% HPLC plus a microbial sterility panel
- RETP002 99.262% Longest-standing record · tested 04 Nov 2025
Latest Research
126 cited articles covering receptor pathways, trial readouts, regulatory status, COA verification methodology, stability and handling, and compound comparisons. Every numeric claim is sourced to a trial, a regulator, or a published batch report — see our research standards for how that is enforced.
Peptide Research Categories
For Research Use Only
Third-Party Tested.
Still Checkable.
These are archived third-party analytical records, published so that every purity figure cited across this site stays traceable to its source report. Each batch was tested by Janoshik Analytical, an independent laboratory specialising in peptide purity analysis. Remy Peptides no longer supplies research materials — the reports remain online as reference. Four flagship reports below; the full set sits in the COA archive.
Full record set: the batch record index, the Janoshik verification walkthrough, the HPLC purity guide, and the retatrutide format and evidence overview.
Four checks. Any report.
Match the identifiers
Confirm the laboratory
Read the whole panel
Re-verify at source
Three receptors.
One compound.
Retatrutide is an investigational peptide and triple hormone receptor agonist studied in metabolic research — it acts on three hormone pathways at once. Retatrutide targets three receptors—GLP-1, GIP, and glucagon—and this triple receptor mechanism is what sets it apart in the incretin literature, while it remains in Phase 3 clinical trials. Every batch figure cited on this site comes from an independent Janoshik report published in the COA archive, all above 99% HPLC purity. For receptor-pathway details, trial references, and compound comparisons, read the full research comparison or the GLP-1, GIP and glucagon mechanism explainer.
Glucagon-Like Peptide
Glucose-Dependent Insulinotropic
Glucagon Receptor
Retatrutide HPLC purity
COA Result
Simultaneously
Activated
Records In The
COA Archive
Prefilled Pens and Lyophilized Vials. Different Handling Maths.
Most retatrutide literature and batch documentation describes one of two physical presentations: solution-state material in a prefilled click-indexed cartridge, or lyophilized powder in a sealed vial. The compound is the same; what changes is the handling chain, the arithmetic a lab has to do, and which analytical panels the batch report can carry. Third-party batch data is what makes either presentation checkable.
Pre-formulated cartridges that arrive already in solution, dispensed in fixed mechanical increments rather than drawn by volume.
- No reconstitution step and no diluent volume to record
- Click-indexed scale — the increment is fixed by the device, so calibration replaces volumetric measurement
- Already in solution, so the stability clock starts before the cartridge is opened
- Click-to-milligram conversion tables: pen clicks guide and the pen calculator
Freeze-dried powder that stays dry until the lab adds diluent, which means the working concentration is decided in the lab rather than at the filling line.
- Requires reconstitution, so diluent choice and volume become recorded variables: bacteriostatic water guide
- Volumetric measurement — concentration maths done per vial: reconstitution calculator
- Dry storage before reconstitution, with a separate and much shorter in-solution stability window afterwards
- Sealed sterile presentation, so batch reports can carry endotoxin and sterility panels
The presentation changes which analytical panels are meaningful, so a like-for-like purity comparison between a pen batch and a vial batch is not a like-for-like comparison of evidence.
- HPLC purity is reported for both presentations
- Sterility and endotoxin appear on the vial line — see RT-40-V-001
- Published HPLC values by batch, presentation and test date in the COA archive
- For in-vitro laboratory research only
Compound Profiles
Mechanism-level reference profiles for the peptides most often researched alongside the incretin compounds — each one opening its cited research article.
Frequently Asked
What is retatrutide?
Is retatrutide approved in the UAE?
How do retatrutide trial outcomes compare to semaglutide?
What side effects are reported in the trials?
What does a published HPLC purity figure actually mean?
How can I verify the Janoshik reports published here?
How should research peptides be stored and handled?
Why is everything on this site labelled For Research Use Only?
Wrong figure? Tell us.
If a citation, batch figure, trial number, or approval status on this site looks wrong or out of date, write to info@remypeptides.com and point at the page — corrections are made against the source, not the summary. How claims are sourced and reviewed is documented in our research standards and editorial policy. Nothing here is medical, dosing, or human-use guidance: any clinical question belongs with a qualified healthcare professional, and approved medicines are dispensed by licensed pharmacies.
Remy Research
Visit Remy Research, our separately operated sister site. Its lab-results library provides additional batch reports to read alongside the research and archived certificates published here. Remy Peptides remains an informational site with research calculators; it does not sell items or accept orders.